Healthcare/Biotech Analysts discuss Jasper Therapeutics’ FDA clearance for their Investigational New Drug (IND) application for a dose escalation Phase Ib/IIa study of its CD117 (c-KIT) targeted antibody briquilimab in chronic spontaneous urticaria (CSU) on an Analyst/Industry conference call to be held on October 11 at 8 am.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JSPR:
- William Blair healthcare/biotech analysts hold analyst/industry conference call
- Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023
- Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria
- Jasper receives IND clearance for Phase 1b/2a study of subcutaneous briquilimab
- Jasper Therapeutics appoints Herb Cross CFO